ARQT
Price
$32.82
Change
+$0.93 (+2.92%)
Updated
Oct 20 closing price
Capitalization
4.13B
6 days until earnings call
Intraday BUY SELL Signals
REGN
Price
$807.48
Change
+$25.44 (+3.25%)
Updated
Oct 20 closing price
Capitalization
83.13B
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs REGN

ARQT vs REGN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARQT vs. REGN commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a StrongBuy and REGN is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARQT with price predictions
Oct 20, 2026

Aroon Indicator for ARQT shows an upward move is likely

ARQT's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator showed a similar pattern. In 199 of the 222 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ARQT as a result. In 76 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +13.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ARQT broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.702) is normal, around the industry mean (3.009). ARQT's P/E Ratio (149.182) is considerably higher than the industry average of (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for REGN with price predictions
Oct 19, 2026

REGN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for REGN turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Indicator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 57 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

Following a +5.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 207 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

REGN moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for REGN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

REGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.622) is normal, around the industry mean (2.978). P/E Ratio (19.285) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.005) settles around the average of (134.267) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (438.009).

FUNDAMENTALS RATINGS
ARQT vs REGN: Fundamental Ratings
ARQT
REGN
OUTLOOK RATING
1..100
3811
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
7586
SMR RATING
1..100
5459
PRICE GROWTH RATING
1..100
3650
P/E GROWTH RATING
1..100
2116
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (88) in the Biotechnology industry is in the same range as ARQT (99) in the null industry. This means that REGN’s stock grew similarly to ARQT’s over the last 12 months.

ARQT's Profit vs Risk Rating (75) in the null industry is in the same range as REGN (86) in the Biotechnology industry. This means that ARQT’s stock grew similarly to REGN’s over the last 12 months.

ARQT's SMR Rating (54) in the null industry is in the same range as REGN (59) in the Biotechnology industry. This means that ARQT’s stock grew similarly to REGN’s over the last 12 months.

ARQT's Price Growth Rating (36) in the null industry is in the same range as REGN (50) in the Biotechnology industry. This means that ARQT’s stock grew similarly to REGN’s over the last 12 months.

REGN's P/E Growth Rating (16) in the Biotechnology industry is in the same range as ARQT (21) in the null industry. This means that REGN’s stock grew similarly to ARQT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARQTREGN
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
61%
Momentum
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 2 days ago
61%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 6 days ago
65%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 2 days ago
56%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 2 days ago
60%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
68%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (ARQT: $32.82 vs. REGN: $807.48)
Brand notoriety: ARQT: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 164% vs. REGN: 82%
Market capitalization -- ARQT: $4.13B vs. REGN: $83.13B
ARQT [@Biotechnology] is valued at $4.13B. REGN’s [@Biotechnology] market capitalization is $83.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 1 FA rating(s) are green while REGN’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARQT and REGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 6 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • ARQT’s TA Score: 6 bullish, 4 bearish.
  • REGN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARQT is a better buy in the short-term than REGN.

Price Growth

ARQT (@Biotechnology) experienced а +25.80% price change this week, while REGN (@Biotechnology) price change was +7.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.

Reported Earning Dates

ARQT is expected to report earnings on Oct 27, 2026.

REGN is expected to report earnings on Oct 30, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARQT
Daily Signal:
Gain/Loss:
REGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DFH9.590.94
+10.87%
Dream Finders Homes
GTBP7.310.62
+9.27%
GT Biopharma Inc
DTIL6.560.37
+5.98%
Precision BioSciences
CTSH68.181.39
+2.08%
Cognizant Technology Solutions Corp
ABCL11.71-0.22
-1.84%
AbCellera Biologics

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+3.25%
VRTX - REGN
43%
Loosely correlated
+2.53%
RPRX - REGN
36%
Loosely correlated
+3.29%
BMRN - REGN
36%
Loosely correlated
+3.24%
ARQT - REGN
36%
Loosely correlated
+2.92%
INCY - REGN
33%
Loosely correlated
+2.97%
More